Cargando…
An Integrated Bioinformatics Analysis Repurposes an Antihelminthic Drug Niclosamide for Treating HMGA2-Overexpressing Human Colorectal Cancer
Aberrant overexpression of high mobility group AT-hook 2 (HMGA2) is frequently found in cancers and HMGA2 has been considered an anticancer therapeutic target. In this study, a pan-cancer genomics survey based on Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) data indicated...
Autores principales: | Leung, Stephen Wan, Chou, Chia-Jung, Huang, Tsui-Chin, Yang, Pei-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826424/ https://www.ncbi.nlm.nih.gov/pubmed/31581665 http://dx.doi.org/10.3390/cancers11101482 |
Ejemplares similares
-
Niclosamide: Beyond an antihelminthic drug
por: Chen, Wei, et al.
Publicado: (2018) -
Antihelminthic niclosamide modulates dendritic cells activation and function
por: Wu, Chieh-Shan, et al.
Publicado: (2014) -
Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer
por: Lin, Chi-Kang, et al.
Publicado: (2016) -
The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo
por: Zhou, Jingfeng, et al.
Publicado: (2017) -
The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo: Erratum
por: Zhou, Jingfeng, et al.
Publicado: (2020)